Jeries Kort, M.D.

Professional Background

A highly skilled hematologist and oncologist with a comprehensive academic and clinical background. Currently serving as an Assistant Professor at the University of Kansas Medical Center, specializing in Plasma Cell Disorders. Earned an MD from Al-Quds University in Jerusalem, followed by rigorous international training at the American University of Beirut. Completed residency training in Internal Medicine, followed by a fellowship in Hematology and Oncology, including a Chief Fellowship at Case Western Reserve University and University Hospitals. Recipient of prestigious awards, including the SOHO Young Investigator Award and the Harold C. Klein Humanism Award, demonstrating a strong commitment to advancing cancer therapies and improving patient outcomes. Contributed extensively to peer-reviewed literature and regularly presented at international scientific conferences, promoting interdisciplinary collaboration and ongoing advancements in the field.

• MD, MD, Al-Quds University- Jerusalem, Palestine
• Internship, Internal Medicine, Palestine Medical Complex- Ramallah, Palestine
• Residency, Internal Medicine, Al-Makassed Hospital- Jerusalem, Palestine
• Residency, Internal Medicine, American University of Beirut Medical Center- Beirut, Lebanon
• Residency, Internal Medicine, University Hospitals/Case Western Reserve University- Cleveland, Ohio
• Clinical Fellowship, Hematology-Oncology, Case Western Reserve University- Cleveland, Ohio
• Clinical Fellowship, Hematology-Oncology, Case Western Reserve University- Cleveland, Ohio

• American Board of Internal Medicine- Internal Medicine, American Board of Internal Medicine
• Kansas State License, Kansas State Board of Healing Arts

• International Myeloma Society , Member, 2022 - 2026
• American Society for Transplantation and Cellular Therapy , Member, 2019 - 2026
• American Society of Clinical Oncology , Member, 2019 - 2026
• American Society of Hematology , Member, 2019 - 2026
• European Society of Blood and Marrow Transplantation , Member, 2018 - 2023
• Society of Hematologic Oncology , Member, 2018 - 2026

---

• Koubar, S., H, Kort, J, Kawtharani, S, Chaaya, M, Makki, M, Uthman, I. 2019. Characteristics of lupus and lupus nephritis at a tertiary care center in Lebanon. Lupus, 28 (13), 1598-1603. https://doi.org/10.1177/0961203319877459
• El Sayed, Rola, El Jamal, Lara, El Iskandarani, Sarah, Kort, Jeries, Abdel Salam, Mahmoud, Assi, Hazem. 2019. Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials. Frontiers in Oncology, 9. https://doi.org/10.3389/fonc.2019.00510
• Kort, Jeries, Chidiac, Amanda, El Sayed, Rola, Massoud, Radwan, Nehme, Rita, Bazarbachi, Ali, El-Cheikh, Jean. 2020. Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma. Leukemia & Lymphoma, 61 (7), 1732-1735. https://doi.org/10.1080/10428194.2020.1728755
• El Sayed, Rola, El Darsa, Haidar, Kort, Jeries, Al Chami, Farouk, Ibrahim, Ali, Charafeddine, Maya, Bazarbachi, Ali, Abou Dalle, Iman, El Cheikh, Jean. 2021. Safety and Efficacy of Replacing Vindesine with Vincristine in R-ACVBP Regimen for the Treatment of Large B Cell Lymphomas. Clinical Lymphoma Myeloma and Leukemia, 21 (10), 711-719. https://doi.org/10.1016/j.clml.2021.05.011
• Rana, P., S, Murphy, E., V, Kort, J, Driscoll, J., J. 2022. Road testing new CAR design strategies in multiple myeloma.. Frontiers in immunology, 13, 957157
• Malek, Ehsan, Kort, Jeries, Metheny, Leland, Fu, Pingfu, Li, Gen, Hari, Parameswaran, Efebera, Yvonne, Callander, Natalie., S., Qazilbash, Muzaffar., H., Giralt, Sergio, Krishnan, Amrita, Stadtmauer, Edward., A., Lazarus, Hillard., M.. 2024. Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial. Transplantation and Cellular Therapy, 30 (7), 698.e1-698.e10. https://doi.org/10.1016/j.jtct.2024.01.053
• Doumeth, Sarah., Abi, Kort, Jeries, Pamuk, Omer., Nuri. 2024. Blood-dominant disease in late-and-early-onset lupus: A systematic review and meta-analysis. Autoimmunity Reviews, 23 (11), 103652. https://doi.org/10.1016/j.autrev.2024.103652
• Kort, Jeries, Naleid, Nikolas, Oley, Frank, Ignatz-Hoover, James, Margevicius, Seunghee, Fu, Pingfu, Malek, Ehsan, Cooper, Brenda. 2025. Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.02.004